Xinyi Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinyi Lou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Botai Li
Shanghai Jiao Tong University 2 Shanghai
9 shared publications - Bowen Xie
Institute for Immunology, Tsinghua University, Beijing, China
9 shared publications - Chen Dong
Westlake University School of Medicine, Hangzhou, China
9 shared publications - Peng Wei
Institute for Immunology, Tsinghua University, Beijing, China
9 shared publications - Ting Zhang
Shanghai Jiao Tong University 5 Shnghai
9 shared publications - Xiaoshuang Wang
Tsinghua University 3 Beijing
9 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Pancreatic cancer responds poorly to immunotherapy, primarily due to poor activation of CD8+ T cells and their limited infiltration into the tumor tissue. Strategies to enhance CD8+ T-cell priming and function are therefore critical for improving immunotherapeutic efficacy in pancreatic cancer. The RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) plays a pivotal role in maintaining immune homeostasis. In this study, we found that ADAR1 expression positively correlates with pancreatic cancer progression. Depletion of ADAR1 in tumor cells resulted in excessive production of interferon β, which increased the abundance and activation of conventional type 1 dendritic cells. This alteration enhanced CD8+ T-cell recruitment and activation, ultimately sensitizing pancreatic cancer to immunotherapy. Collectively, our findings support ADAR1 inhibition combined with immunotherapy as a promising therapeutic strategy for pancreatic cancer.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Pancreatic cancer responds poorly to immunotherapy, primarily due to poor activation of CD8+ T cells and their limited infiltration into the tumor tissue. Strategies to enhance CD8+ T-cell priming and function are therefore critical for improving immunotherapeutic efficacy in pancreatic cancer. The RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) plays a pivotal role in maintaining immune homeostasis. In this study, we found that ADAR1 expression positively correlates with pancreatic cancer progression. Depletion of ADAR1 in tumor cells resulted in excessive production of interferon β, which increased the abundance and activation of conventional type 1 dendritic cells. This alteration enhanced CD8+ T-cell recruitment and activation, ultimately sensitizing pancreatic cancer to immunotherapy. Collectively, our findings support ADAR1 inhibition combined with immunotherapy as a promising therapeutic strategy for pancreatic cancer.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 1. ADAR1 is upregulated in human pancreatic cancer tissues.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 1. ADAR1 is upregulated in human pancreatic cancer tissues.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 6. Tumor cell-derived IFNβ activates cDC1s and suppresses tumor progression.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 6. Tumor cell-derived IFNβ activates cDC1s and suppresses tumor progression.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 3. Loss of ADAR1 increases CD8+ T cells infiltration.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 3. Loss of ADAR1 increases CD8+ T cells infiltration.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 2. Flow cytometry gating strategies and representative plots.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 2. Flow cytometry gating strategies and representative plots.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Tables from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Tables from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 4. Loss of ADAR1 increases CD8+ T cells infiltration and activation.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 4. Loss of ADAR1 increases CD8+ T cells infiltration and activation.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 5. ADAR1 restricts activation of interferon signaling pathway.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from ADAR1 Deficiency in Pancreatic Cancer Cells Potentiates cDC1 Activation and Promotes Sensitization to Immunotherapy
Supplementary Figure 5. ADAR1 restricts activation of interferon signaling pathway.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (9) , 1386-1399
ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy
Pancreatic cancer responds poorly to immunotherapy, primarily due to poor activation of CD8+ T cells and their limited infiltration into the tumor tissue. Strategies to enhance CD8+ T-cell priming and function are therefore critical for improving immunotherapeutic efficacy in pancreatic cancer. The RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) plays a pivotal role in maintaining immune homeostasis. In this study, we found that ADAR1 expression positively correlates with pancreatic cancer progression. Depletion of ADAR1 in tumor cells resulted in excessive production of IFNβ, which increased the abundance and activation of conventional type 1 dendritic cells (cDC1s). This alteration enhanced CD8+ T-cell recruitment and activation, ultimately sensitizing pancreatic cancer to immunotherapy. Collectively, our findings support ADAR1 inhibition combined with immunotherapy as a promising therapeutic strategy for pancreatic cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (9) , 1386-1399
ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy
Pancreatic cancer responds poorly to immunotherapy, primarily due to poor activation of CD8+ T cells and their limited infiltration into the tumor tissue. Strategies to enhance CD8+ T-cell priming and function are therefore critical for improving immunotherapeutic efficacy in pancreatic cancer. The RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) plays a pivotal role in maintaining immune homeostasis. In this study, we found that ADAR1 expression positively correlates with pancreatic cancer progression. Depletion of ADAR1 in tumor cells resulted in excessive production of IFNβ, which increased the abundance and activation of conventional type 1 dendritic cells (cDC1s). This alteration enhanced CD8+ T-cell recruitment and activation, ultimately sensitizing pancreatic cancer to immunotherapy. Collectively, our findings support ADAR1 inhibition combined with immunotherapy as a promising therapeutic strategy for pancreatic cancer.